By Frank Curzio in Growth Stock Wire:

In the past four months, [medical device maker Boston Scientific] had to pay Johnson & Johnson a $1.7 billion settlement. Then, management lowered its full-year earnings guidance. Finally, in mid-March, the FDA ordered the company to pull all of its implantable cardioverter defibrillators (ICDs) from the market. ICDs account for about 15% of BSX's revenue. Shares collapsed to a 10-year low.

Saying that BSX has had its share of problems is an understatement. In other words, I understand why my readers and a whole lot of other folks hate this stock. But based on my research, there's huge upside from these levels. Let me explain why...

Read full article...

More on stocks:

A beaten-down sector to buy immediately

A foolproof way to earn big dividends from safe stocks

Porter Stansberry: The only stocks new investors should buy